Coherus Reveals US Launch Plans For Interchangeable Ranibizumab
Pricing Details Set Out Ahead Of 3 October Launch For Cimerli Biosimilar Version Of Lucentis
Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.
You may also be interested in...
Xbrane Refiles Ranibizumab With US FDA
Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.
Biogen Launches Lucentis Biosimilar Byooviz In Canada
Biogen has launched the Samsung Bioepis-developed Byooviz version of Lucentis in Canada, marking the first and only ranibizumab biosimilar to be approved and introduced in the market.
Xbrane Estimates Q1 2023 Resubmission For US Lucentis Biosimilar
Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.